NM_001034853.2(RPGR):c.865A>G (p.Ile289Val) is a missense variant predicted to cause substitution of isoleucine by valine at amino acid 289. This variant is present in gnomAD v.4.1.0 at a frequency of 0.0001308 among hemizygous individuals, with 51 variant alleles / 389,832 total hemizygous alleles, which is higher than the ClinGen X-linked IRD VCEP BA1 threshold of >0.00005 (BA1). The variant co-segregates with X-linked retinitis pigmentosa or milder phenotypes in female carriers across 5 meioses in a single family, however, the description of phenotypes is insufficiently detailed to meet PP4 or PP1 (PMID: 10482958). This variant has been reported in at least 2 apparently unrelated probands meeting one of the PS4 requirements of a male with some functional vision impairment by age 30 and/or decreased or absent ERG responses, or a female with functional visual abnormality and documentation of a male relative affected with retinitis pigmentosa (PMIDs: 32531858, 28863407). However, because the variant meets BA1, PS4_Supporting cannot be met. The variant protein exhibits decreased interaction with RPGRIP1 in a yeast-2-hybrid assay (PMID: 23213406, PS3_Supporting). The computational predictor REVEL gives the variant a score of 0.553, which is above the ClinGen X-linked IRD VCEP BP4 threshold of <0.290 and below the PP3 threshold of >0.644, so BP4 and PP3 are not met. The computational splicing predictor SpliceAI gives the variant a delta score of 0.01 for acceptor gain, which is below the ClinGen X-linked IRD VCEP BP4 threshold of <0.2 and indicates that the variant has no predicted impact on splicing. In summary, this variant meets the criteria to be classified as benign for RPGR-related retinopathy based on the ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPGR Version 1.0.0; BA1 and PS3_Supporting. (date of approval 05/16/2025).